News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica’s
Latest News
PRESS RELEASES

Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal
Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations, demonstrating the company’s commitment to advancing healthcare through cutting-edge research and development.
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship
UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA.
Announcements
Catch up on Isogenica’s latest activities.
Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal
Isogenica, a leading innovator in VHH antibodies, is proud to unveil two significant collaborations, demonstrating the company’s commitment to advancing healthcare through cutting-edge research and development.
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
Isogenica turns 25: Our journey
We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Here’s the story…
Webinars
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Nature Webinar
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...

Resources
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
The golden age of bi-specific antibodies is here
Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a renaissance in the design and application of these molecules.
On the Origin of VHHs: Student serendipity and coincidental camels
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
Upcoming
Events
Isogenica are always looking to learn and connect at upcoming events and conferences.

Events
Isogenica’s
Newsletters
Catch up with Isogenica’s news and activies through the latest Newsletters.
🩸 This month we’re talking blood cancer and bi-specifics
Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….
🎂 Join us in celebrating our 25th birthday
Not many Biotechs get to turn 25, but this month at Isogenica we are celebrating our quarter century! This edition we look back through our 25 years of new technologies, acknowledging our wonderful partnerships….
📣 Synthetic libraries are our forte and here’s why…
This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London….